CD8A and ovarian cancer: The existence of dysfunctional (CD8+PD-1+) or terminally dysfunctional (CD8+PD-1+TOX+) T cells, along with their interaction with PD-L1+ cells, independently predicted a 24-month PFS in patients with dMMR uterine or ovarian cancers treated with nivolumab (26).